‘The GAVI Vaccine Alliance is in talks with COVID-19 vaccine manufacturers including China's state-owned Sinopharm to expand the COVAX pipeline and secure doses for distribution, a GAVI spokeswoman said on Monday.
‘Sinopharm received emergency use listing from the World Health Organization (WHO) last Friday, making it eligible for the COVAX programme and bolstering Beijing's push for a bigger role in inoculating the world.
‘COVAX, run jointly by GAVI and the WHO to provide doses to the world's poorest people, has hit major supply problems. To date the AstraZeneca (AZN.L) shot made by the Serum Institute of India account for most doses rolled out, but authorities there have restricted exports because of India's massive epidemic.’
Read here (Reuters, May 10, 2021)
